Search

China pledges to reach a peak in CO 2 emissions by 2030 and to make its best efforts to reach this peak earlier. Previous studies have paid much attention to the total amount of China's CO 2 emissions, but usually only one dataset is used in each evaluation. The pledged national reduction target is administratively divided into provincial targets. Accurate interpretation of province-level carbon emissions is essential for making policies and achieving the reduction target. However, the spatiotemporal pattern of provincial emissions and the associated uncertainty are still poorly understood. Thus, an assessment of province-level CO 2 emissions considering local statistical data and emission factors is urgently needed. Here, we collected and analyzed 7 published emission datasets to comprehensively evaluate the spatiotemporal distribution of provincial CO 2 emissions. We found that the provincial emissions ranged from 20 to 649 Mt CO 2 and that the standard deviations (SDs) ranged from 8 to 159 Mt. Furthermore, the emissions estimated from provincial-data-based inventories were more consistent than those from the spatial disaggregation of national energy statistics, with mean SDs of 26 and 65 Mt CO 2 in 2012, respectively. Temporally, emissions in most provinces increased from 2000 to approximately 2012 and leveled off afterwards. The interannual variation in provincial CO 2 emissions was captured by provincial-data-based inventories but generally missed by national-data-based inventories. When compared with referenced inventories, the discrepancy for provincial estimates could reach −57%–162% for national-data-based inventories but were less than 45% for provincial-data-based inventories. Using comprehensive data sets, the range presented here incorporated more factors and showed potential systematic biases. Our results indicate that it is more suitable to use provincial inventories when making policies for subnational CO 2 reductions or when performing atmospheric CO 2 simulations. To reduce uncertainties in provincial emission estimates, we suggest the use of local optimized coal emission factors and validations of inventories by direct measurement data and remote sensing results. • Estimates from provincial statistics were more consistent than the national ones. • The interannual variations were well-captured by provincial-data-based datasets. • The provincial-based estimates help to allocate duties and set reduction targets. [ABSTRACT FROM AUTHOR]

Vascular depression can respond poorly to antidepressants. This study aimed to explore the efficacy and safety of tandospirone plus escitalopram for treating vascular depression with anxiety. This pilot randomized controlled trial included consecutive inpatients/outpatients with vascular depression/anxiety at the Department of Neurology, Fujian Medical University Union Hospital, China (January 2014 to December 2016). Among 157 patients screened, 100 were randomly divided into the tandospirone + escitalopram (combination therapy) and escitalopram (monotherapy) groups equally, and then followed for 8 weeks. Efficacy was evaluated using the Hamilton Depression (HAMD), Hamilton Anxiety (HAMA), Clinical Global Impression (CGI) and Mini-Mental State examination (MMSE) scales. Adverse events (AEs) were assessed with the Treatment Emergent Symptom Scale (TESS). HAMD and HAMA scores decreased progressively, showing reductions versus baseline at 1, 2, 4 and 8 weeks in both groups (P < 0.001). HAMD and HAMA scores were lower in the tandospirone + escitalopram group than those in the escitalopram group at 1 and 2 weeks (P < 0.001), but not at 4 and 8 weeks. Improvements in CGI scores (severity, improvement and efficacy indexes) were greater in the tandospirone + escitalopram group than that in the escitalopram group at 1 and 2 weeks (P < 0.01), but not at 4 and 8 weeks. The tandospirone + escitalopram group had higher MMSE scores than that in the escitalopram group at 4 and 8 weeks (P < 0.01). All AEs were mild, and the rates were comparable between groups. Augmentation of escitalopram with tandospirone accelerates the onset of anti-depressive and anxiolytic effects and improves cognitive function in patients with vascular depression and anxiety. [ABSTRACT FROM AUTHOR]